Image

LUDGER JOHANNES

Doctor,
Research Director Inserm
Recherche - Paris
Spécialités / domaines
Cell biology,
Chimie-Biologie
Functions within Institut Curie:
Présentation

Ludger Johannes (PhD) is Research Director (DRE) at INSERM. Since the beginning of his biochemistry undergraduate studies in 1987, he is member of the Studienstiftung des Deutschen Volkes (German organization of the academically gifted), since 1993 of Boehringer Ingelheim Fonds, since 2012 of the European Molecular Biology Organization (EMBO), and since 2019 of the German Academy of Science — Leopoldina. He serves on editorial boards of international journals (PLoS One and Toxins). At Institut Curie, he is heading since 2001 the Traffic, Signaling and Delivery Team, member of the excellence initiative Cell(n)Scale. Since January 2014, he directs the Cellular and Chemical Biology unit (U1143 INSERM — UMR3666 CNRS). His research aims at establishing fundamental concepts of endocytosis and intracellular trafficking. The Johannes team has made two major contributions in this context: The discovery of the membrane trafficking interface between early endosomes and the Golgi apparatus which has since become a focus of cell biology research, and the demonstration that dynamic lectin-induced glycolipid reorganization acts as a driving force for endocytic pit construction in clathrin-independent endocytosis. The latter was termed GlycoLipid-Lectin (GL-Lect) hypothesis. The studies of the Johannes team are very well cited and have been published in several highly visible journals, including Cell, Nature, Nature Cell Biology, and Nature Nanotechnology. Between 2014-2020, he was the holder of an ERC advanced grant. He also aims at exploiting the discoveries of his team in fundamental membrane biology research for the development of innovative cancer therapy strategies. His team has notably validated the B-subunit of Shiga toxin (STxB) as a "pilot" for the delivery of therapeutic compounds to precise intracellular locations of dendritic cells for immunotherapy, and to tumors for targeted therapy (12 patent families, 5 of which are delivered in the US, Europe and other countries; creation of biotech companies).

Publications
PSL Chemical Biology Symposia Third Edition: A Branch of Science in its Explosive Phase
ChemBioChem
Leeroy Baron, Justine Hadjerci, Leishemba Thoidingjam, Marina Plays, Romain Bucci, Nolwenn Morris, Sebastian Müller, Fabien Sindikubwabo, Stéphanie Solier, Tatiana Cañeque, Ludovic Colombeau, Cedric M. Blouin, Christophe Lamaze, Alain Puisieux, Yannick Bono, Christine Gaillet, Luca Laraia, Boris Vauzeilles, Frédéric Taran, Sébastien Papot, Philippe Karoyan, Romain Duval, Florence Mahuteau‐Betzer, Paola Arimondo, Kevin Cariou, Gilles Guichard, Laurent Micouin, Mélanie Ethève‐Quelquejeu, Daniela Verga, Antoine Versini, Gilles Gasser, Cong Tang, Philippe Belmont, Andreas Linkermann, Claudia Bonfio, Dennis Gillingham, Thomas Poulsen, Marco Di Antonio, Marie Lopez, Dominique Guianvarc'h, Christophe Thomas, Géraldine Masson, Arnaud Gautier, Ludger Johannes, Raphaël Rodriguez
Glycolipid-dependent and lectin-driven transcytosis in mouse enterocytes
Communications Biology
Alena Ivashenka, Christian Wunder, Valerie Chambon, Roger Sandhoff, Richard Jennemann, Estelle Dransart, Katrina Podsypanina, Bérangère Lombard, Damarys Loew, Christophe Lamaze, Francoise Poirier, Hermann-Josef Gröne, Ludger Johannes, Massiullah Shafaq-Zadah
Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
EMBO Molecular Medicine
Chiara Soldati, Irene Lopez‐Fabuel, Luca G Wanderlingh, Marina Garcia‐Macia, Jlenia Monfregola, Alessandra Esposito, Gennaro Napolitano, Marta Guevara‐Ferrer, Anna Scotto Rosato, Einar K Krogsaeter, Dominik Paquet, Christian M Grimm, Sandro Montefusco, Thomas Braulke, Stephan Storch, Sara E Mole, Maria A De Matteis, Andrea Ballabio, Julio L Sampaio, Tristan McKay, Ludger Johannes, Juan P Bolaños, Diego L Medina